Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

47.51USD
4:00pm EDT
Change (% chg)

$-0.61 (-1.27%)
Prev Close
$48.12
Open
$48.09
Day's High
$49.32
Day's Low
$47.40
Volume
156,908
Avg. Vol
349,021
52-wk High
$82.68
52-wk Low
$33.06

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $1,289.79
Shares Outstanding(Mil.): 26.80
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -6.74 -- --
ROI: -105.99 2.89 12.63
ROE: -106.03 1.65 14.82

BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint

* ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT

May 23 2018

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.

May 23 2018

BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID

May 02 2018

BRIEF-Esperion Posts Qtrly Loss Per Share $1.73

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 02 2018

UPDATE 1-Esperion's drug clears study as add-on cholesterol treatment

March 27 Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment to lower the risk of artery-clogging heart disease.

Mar 27 2018

Esperion's cholesterol drug succeeds in mid-stage study

March 27 Esperion Therapeutics Inc said on Tuesday a mid-stage study of its experimental oral drug met the main goal of reducing cholesterol.

Mar 27 2018

BRIEF-Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA

Mar 27 2018

Esperion's cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

Mar 07 2018

UPDATE 1-Esperion's cholesterol drug succeeds in late-stage study

March 7 Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

Mar 07 2018

BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID

Mar 07 2018

Earnings vs. Estimates